Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Brimonidine is effective for reducing facial redness in skin conditions and has potential for broader dermatological uses.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Children with partial biotinidase deficiency are healthy at birth but may develop symptoms that improve with biotin therapy.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Mutations in the KLHL24 gene cause skin blistering in epidermolysis bullosa simplex.

The protein folliculin, involved in a rare disease, works with another protein to control how cells stick together and their organization, and changes in this interaction can lead to disease symptoms.

Newborn screening for biotinidase deficiency is effective in preventing severe complications.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Brassinosteroids may be useful in treating cancer, infections, and other diseases.

Basonuclin may help control ribosomal RNA gene activity in skin cells.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Butin is effective in treating vitiligo in mice.

Improved CRBN ligands make protein degraders more effective and drug-like.

Biotin helps maintain hair follicle growth by affecting cell death and survival signals.

BMPR1a-ECD reduces wrinkles much more effectively than retinoic acid.

Biotin and biotinidase are essential to prevent health issues, and deficiencies require lifelong supplementation.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.

Folliculin deficiency causes problems with cell division and positioning due to disrupted RhoA signaling and interaction with p0071.

Baricitinib was effective in treating both early and late onset alopecia areata.

Baicalin may effectively treat hair loss by inhibiting 5α-reductase.

Biotin supplements did not significantly reduce hair loss in rats on valproic acid.

A new mutation in the PLEC gene causes a rare condition with skin blistering, muscle weakness, and hair loss.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.